Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
376 Leser
Artikel bewerten:
(1)

Lydia Seymour joins Cambridge Healthcare Research as Head of HR, formerly of Abcam and Fluidigm

CHR enhances internal talent and leadership development with appointment

CAMBRIDGE, England, Nov. 12, 2020 /PRNewswire/ -- 2020 winners of the Queen's Award for Enterprise Cambridge Healthcare Research (CHR), and its market research division Vox.Bio, announces the appointment of Lydia Seymour as Head of HR.

Cambridge Healthcare Research Logo

Lydia brings to the group two decades of experience in leadership development and talent management on a global scale. Lydia will report to CEO Chris Stevenson.

Commenting on the appointment, Chris said, "At CHR, our success is rooted in the quality of our work, and that quality comes from the passion of our people - our team is at the heart of everything we do. Even during the pandemic, we have seen a rapid expansion in our workforce, welcoming over 30 new colleagues since the beginning of the year. Lydia's strong track record and rich experience in talent development and change management across international teams, will help us continue to build an agile culture of inclusivity and personal growth for all, while attracting future talent to meet the evolving needs of our clients. I am delighted to welcome Lydia to the team."

Lydia is an experienced HR leader with extensive expertise in successfully shaping and leading employee engagement and development programs, implementing reward and talent management strategies and delivering transformational change. She holds a post graduate diploma from the Chartered Institute of Personnel and Development and an MA in HR Management from Anglia Ruskin University. Lydia joins CHR from Fluidigm Corporation, where she was responsible for leading business partner activities throughout the European region. With over 20 years in the life sciences and consulting services sectors, supporting commercial, technical and corporate teams globally, particularly in the US and APAC, her previous career included time at Abcam, TTP Group and Xaar plc.

About Cambridge Healthcare Research

Cambridge Healthcare Research is a management consultancy providing strategic decision support to the pharmaceutical, medical device and consumer healthcare industries. Working closely with clients on asset commercialisation, product strategy and future opportunities, CHR enables its partners to navigate difficult commercial decisions, mapping their position in complex markets, and outlining the impact of competitor activities, intent and capabilities on their success. Vox.Bio is CHR's dynamic healthcare market research agency, re-thinking healthcare market research to delivering meaningful insights to clients in pharmaceutical, consumer health and medical device industries.

The team is passionate about healthcare and medical innovation, and its evaluation of market dynamics - combined with a targeted understanding of key trends in the prescriber, regulator and payer environments - equips their clients to make the right decisions from an optimally informed position.

In 2020, CHR won The Queen's Award for Enterprise in International Trade. The team spans global healthcare markets, with offices in Cambridge and London as well as consultants located across Europe, Asia and North America.

For further information please contact:

Edward Cartwright
media@camhcr.com
Twitter, LinkedIn, Queen's Award, Queen's Award Video
+44-1223-900-191

Related Links

http://www.camhcr.com
https://vox.bio/

Logo: https://mma.prnewswire.com/media/1157854/Cambridge_Healthcare_Research_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.